Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
|Poll|September 10, 2019
A 35-Year-Old Woman with Dyspnea
Author(s)Cesar A. Moran, MD
A 35-year-old woman presents with symptoms of dyspnea. Chest films detects the presence of an anterior mediastinal cystic mass. What is your diagnosis?
Advertisement
A 35-year-old woman presents with symptoms of dyspnea. Chest films detects the presence of an anterior mediastinal cystic mass.
Based on the image shown, what is your diagnosis?
Advertisement
Related to this article
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Longer follow-up is needed for the phase 3 MIDAS trial to determine the impact of MRD conversion on progression-free survival and overall survival.
The FDA cleared TriSalus’s TriNav Advance device, which extends the SmartValve-based drug delivery technology to improve tumor penetration during liver embolization.
In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials
3
SOHO-02 Trial Will Confirm Sevabertinib’s Frontline NSCLC Benefit
4
MELT-MM Regimen Yields Responses in Relapsed/Refractory Multiple Myeloma
5